Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Jan 01

2025

Hua Medicine appoints sales veteran Mr. Lu Yu as Vice President of Sales and Marketing Division

Hua Medicine (the "Company", HKEx: 2552.HK) announced today that the Company appoints Mr. Lu Yu (陆宇) as Vice President of Sales and Marketing Division. Mr. Lu Yu has more than 20 years of experience in multinational pharmaceutical companies and nearly 20 years of experience in diabetes sales and marketing. He is familiar with key diabetes markets nationwide and has extensive experience in managing large-scale management teams.

Nov 30

2024

Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).

Nov 30

2024

Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).

Nov 04

2024

Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"

The 17th "C.C. Tan Life Science Award" ceremony was held in Shenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C.

Nov 01

2024

Hua Medicine Receives Grade A Rating in Shanghai Pharmaceutical Manufacturer Comprehensive Credit Risk Assessment

Recently, in the "2024 Shanghai Pharmaceutical Manufacturer Comprehensive Credit Risk Assessment" authorized by the Shanghai Medical Products Administration, Hua Medicine (Shanghai) Ltd. ("Hua Shanghai") was awarded the highest credit rating of Grade A.

Aug 29

2024

[NEWS] Hua Medicine Announces 2024 Interim Results

Dorzagliatin (trade name: HuaTangNing (华堂宁®)), world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited ("Bayer") and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.

Jun 24

2024

[News] Hua Medicine Announces Potential Effects of the Combination of Dorzagliatin and SGLT-2 Inhibitor at 2024 Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company and its wholly-owned subsidiary, Nanjing AscendRare Pharmaceutical Technology Co., Ltd.(AscendRare), presented a number of basic research findings at the 84th American Diabetes Association (ADA) Annual Scientific Sessions.

Jun 17

2024

[News] Hua Medicine will present multiple research results at the 2024 American Diabetes Association (ADA) Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd.

Apr 26

2024

[News] Hua Medicine Initiated Phase I Clinical Trial of 2nd Gen GKA in the U.S. and Completed Enrollment of First Patient

Hua Medicine (the "Company", HKEx: 2552.HK) announced that the Company has officially initiated its Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.

人生就是搏尊龙(中国优质)股份有限公司人生就是搏尊龙

Media

Company News

Hua Medicine appoints sales veteran Mr. Lu Yu as Vice President of Sales and Marketing Division

Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC

Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate

Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"

Hua Medicine Receives Grade A Rating in Shanghai Pharmaceutical Manufacturer Comprehensive Credit Risk Assessment

[NEWS] Hua Medicine Announces 2024 Interim Results

[News] Hua Medicine Announces Potential Effects of the Combination of Dorzagliatin and SGLT-2 Inhibitor at 2024 Annual Scientific Sessions

[News] Hua Medicine will present multiple research results at the 2024 American Diabetes Association (ADA) Annual Scientific Sessions

[News] Hua Medicine Initiated Phase I Clinical Trial of 2nd Gen GKA in the U.S. and Completed Enrollment of First Patient